Also written by Alicia Ritcey:
Goldman Cuts Blankfein's Pay to $22 Million for 2016
x hide permanently

Big Pharma Is Urged to Report on Links Between Pricing and Pay

Bloomberg

Pharmaceutical companies should be required to regularly report whether there’s a link between drug-pricing strategies and executive-compensation plans, according to a shareholder group. The Interfaith Center on Corporate Responsibility , a coalition of institutional investors with more than $400 billion of assets, said in a statement Wednesday that it submitted proposals for inclusion at the 2018 annual meetings of Abbvie Inc., Amgen Inc., Biogen Inc., Bristol Myers Squibb Co. and Eli Lilly & Co. “An executive compensation incentive program reliant on revenue growth solely from drug price increases is a risky and unsustainable strategy,” the group said in the statement. “The ...

Mentions: Executive Compensation Investors risk